T he renin-angiotensin system is crucial for regulation of sodium homeostasis, vascular tone, angiogenesis, and overall cardiovascular function. Within this complex system, angiotensinogen is released into circulation from the liver and is cleaved into the decapeptide angiotensin I by renin. 1, 2 Angiotensin I is further cleaved into the active octapeptide angiotensin II (AngII) by angiotensinconverting enzyme and the heptapeptide angiotensin 1 to 7 (Ang-(1-7)) by either angiotensin-converting enzyme 2 or various endopeptidases. [2] [3] [4] AngII is the most characterized of the renin-angiotensin system peptides and has been shown to mediate the majority of its physiological functions through the AngII type 1 receptor (AT 1 R).
2,5 AT 1 R activation occurs through heterotrimeric G proteins (G q/11 , G i/o , and G 12/13 ), which in turn activate phospholipase C, inhibit adenylate cyclase, and activate RHO GTPases. 2 Although normal AngII signaling contributes to vascular homeostasis, elevated levels of AngII are deleterious, causing vasoconstriction and oxidative stress, whereas insufficient levels like those seen in the absence of renin activity result in endothelial dysfunction. 2, [5] [6] [7] Ang-(1-7) signaling, mediated by the Mas1 receptor, 8 has been shown to exhibit several protective cardiovascular effects that act antagonistically to elevated pathophysiological levels of AngII. [9] [10] [11] [12] These antagonistic effects include the induction of vasodilation, preservation of endothelial function, the promotion of antifibrotic conditions, and facilitating antihypertrophic effects. 9, 11, [13] [14] [15] [16] [17] However, under conditions of reninangiotensin system suppression, such as in low renin forms of hypertension and during periods of elevated sodium intake, low-dose AngII infusion, which normalizes levels of circulating AngII to physiological concentrations, also improves endothelial function and restores impaired vasodilator ability. 6, 7 These studies suggest that there is a delicate balance of the levels of AngII and Ang-(1-7) in the renin-angiotensin system that is more complex than once thought.
Despite the growing evidence that Ang-(1-7)/Mas1 signaling is biologically important to the renin-angiotensin system, studies on the downstream signaling mechanisms have been limited, especially compared with the more studied AngII/ AT 1 R-axis. It has been shown that attenuation of extracellular signal-related kinases 1/2 (ERK1/2) activation through Ang-(1-7)-induced Mas1 receptor signaling in glomerular mesangial cells occurs through both cAMP and protein kinase A. 3, 18 In addition, Ang-(1-7) treatment preserves endothelial function and regulates vascular oxidative stress through mechanisms involving endothelial nitric oxide synthase and nitric oxide bioavailability. 3, 6, 12 Studies involving human endothelial cells constitutively expressing the Mas1 receptor also suggest that Ang-(1-7) regulation of endothelial nitric oxide synthase signaling may be occurring through the regulation of PI3K (phosphatidylinositol 3-kinase) and serine/threonine protein kinase AKT pathways. 3, 10 In addition, a study using quantitative phosphoproteomics provided insights into Ang-(1-7)-induced phosphorylation changes 19 and a second study using an antibody-based protein assay to monitor Ang-(1-7)-altered protein expression 20 in human endothelial cells. Both these studies indicated global changes in signal transduction, apoptosis, cell cycle, and gene expression regulation. These studies provide a strong initial basis for understanding certain aspects of Ang-(1-7)-mediated Mas1 receptor signaling; however, they do not reveal the components of the proximal signaling complex generated from early Ang-(1-7) stimulation of the Mas1 receptor.
To improve our understanding of the signaling mechanisms behind the protective effects of Ang-(1-7) in the vasculature, we characterized the effects of Ang-(1-7) and compared them with the vascular phenotypes resulting from a low, subpressor dose of AngII treatment in renin-suppressed rat models on high-salt diet. We hypothesized that (1) Ang-(1-7) would display similar effects on angiogenesis and vasodilation compared with the low, subpressor dose of AngII, (2) Ang-(1-7)/Mas1 and AngII/ AT 1 R signaling pathways would overlap, and (3) these pathways converge on a common mechanistic pathway regulating both endothelium-dependent vasodilation and angiogenesis. To test these hypotheses, this study used a combination of investigative techniques including an in vivo electric stimulation rat angiogenesis model, ex vivo middle cerebral artery (MCA) vasodilation in response to acetylcholine, and in vitro endothelial tube formation. These functional analyses were supplemented with proteomic and genomic pathway comparisons, followed by pharmacological targeting of implicated pathways contributing to Ang-(1-7)-mediated angiogenesis and vasodilation in the functional assays. This combined systematic approach provided a detailed insight into the intersection between Ang-(1-7)/Mas1 receptor signaling and low-dose AngII/AT 1 R signaling in the vascular endothelium.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

AngII and Ang-(1-7) Enabled Angiogenesis in Response to Electric Stimulation
We have previously shown that 7 days of electric stimulation in vivo produces a robust angiogenic response in rat models that is eliminated by a high-salt diet and restored by a low, subpressor dose AngII infusion 7, 21 ; this result was replicated for a control in this study ( Figure 1A ). In vivo administration of the AT 1 R antagonist losartan abolished the restorative effect of low-dose AngII infusion, whereas Mas1 receptor antagonist A779 had no effect on the ability of low-dose AngII infusion to restore angiogenesis. This experiment was repeated with Ang-(1-7) infusion and cotreatment with losartan, A779, or vehicle ( Figure 1A ). Vessel density was significantly increased in the Ang-(1-7)-infused rats, as observed with AngII infusion; however, losartan was unable to block the increase in vessel density, resulting from Ang-(1-7) treatment. Rats infused with Ang-(1-7) plus A779 exhibited no significant increase of vessel density, suggesting Ang-(1-7)-restored angiogenesis directly through the Mas1 receptor. Vehicle treatment (without low-dose AngII or Ang-(1-7) infusion) was unable to restore stimulated angiogenesis in Sprague Dawley rats on a high-salt diet. These data suggest that Ang-(1-7) restores stimulated angiogenesis through a Mas1 receptor-dependent signaling pathway and does not depend on AngII activation of the AT 1 R axis ( Figure 1A ).
AngII and Ang-(1-7) Mediated Vasorelaxation Response to Acetylcholine
The effects of low-dose AngII, Ang-(1-7), or vehicle infusion on isolated maximum MCA responses to acetylcholine in Sprague Dawley rats on a high-salt diet is summarized in Figure 1B . As in previous studies, 6, 7 this study shows that acetylcholine does not induce MCA vasodilation in vehicle-treated control rats on a high-salt diet (renin suppressed). A chronic infusion of a low, subpressor dose of AngII or Ang-(1-7) in these renin-suppressed rats restored endothelium-dependent vasodilation in response to acetylcholine. AngII-induced vasodilation was eliminated by cotreatment with AT 1 R antagonist losartan; however, it was not affected by the Mas1 receptor antagonist A779. Similarly, Ang-(1-7)-induced vasodilation in response to acetylcholine was inhibited by cotreatment with A779, but not by losartan. As observed with angiogenesis in the Sprague Dawley rat hindlimb ( Figure 1A ), these data suggest that Ang-(1-7)-mediated vasodilation operates exclusively through a Mas1 receptor-dependent signaling pathway, whereas low-dose AngII-mediated vasodilation is exclusively AT 1 R dependent ( Figure 1B ).
Analysis of Endothelial Cell Mas1 Receptor Signaling Pathways
The in vivo experiments suggested an endothelium-dependent Ang-(1-7)/Mas1 receptor proangiogenesis and provasodilator response. This endothelium-dependent result was recapitulated in preliminary tube formation assays in which rat microvascular endothelial cells (RMVECs) treated with Ang-(1-7) displayed a 16% in tube formation versus the nontreated (P<0.05; n=5). To directly analyze the endotheliumdependent response in relation to Mas1 receptor signaling, a combination of cryolysis, immunoprecipitation, and tandem mass spectrometry (MS/MS) analysis was used on signaling complexes isolated from RMVECs ( Figure 2A ). Fluorescence microscopy experiments confirmed that the Mas1 receptor antibody (sc-135063; Santa Cruz) epitope was intracellular ( Figure I in the online-only Data Supplement). Signaling complexes were then verified for the presence of Mas1 by immunoblot ( Figure 2B ; Figure II in the online-only Data Supplement) according to previous protocols [22] [23] [24] [25] using rabbit anti-rat Mas1 primary antibody (sc-135063; Santa Cruz) at 1:1000 and secondary horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (BioRad) at 1:2000, as well as in the raw MS/MS data ( Figure II in the online-only Data Supplement). In the Ang-(1-7)-stimulated RMVEC signaling complexes, 50 proteins were identified as significantly increased (P<0.05; n=8 plus a technical replicate; 16 total MS runs) compared with nonstimulated RMVECs after application of stringent filters ( Figure 2C ; Table 1; Table I in Signaling involvement includes but is not limited to those above. All proteins indicated passed all stringent filters indicated in the Methods; a prefiltered protein list can be found in Table I in the online-only Data Supplement. AKT indicates serine/threonine protein kinase AKT; Ang-(1-7), angiotensin 1 to 7; CDC42, cell division control protein 42 homolog; ERK, extracellular signal-related kinase; FLT, fms-like tyrosine kinase; GAP, guanine nucleotide activating protein; GEF, guanine nucleotide exchange factor; MAPK, mitogen-activated protein kinase; MAS1, mas-related G-protein-coupled receptor 1; mTOR, mechanistic target of rapamycin; NFκB, nuclear factor κ-light-chain-enhancer of activated B cell; NMDA, N-methyl-D-aspartate receptor 1; p38MAPK, p38 mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; PRKD1, serine/threonine protein kinase D1; RAS, Ras GTPase; and RHO, Rho GTPase.
* Table 1 ). Calcium signaling regulators essential for G-protein and other signaling pathways were also observed, such as diacylglycerol kinase, PI3K, and protein kinase C (Table 1) . AKT1 and nuclear factor κ-lightchain-enhancer of activated B cells (NFκB) regulators, such as mTOR (mechanistic target of rapamycin) and CARD10 (caspase recruitment domain family member 10), essential for cell regulation of inflammatory response were present as well (Table 1) . CARD10, an important activator of NFκB, was detected in significantly lower amounts in the stimulated receptor complex, suggesting a decrease in activation and a potential anti-inflammatory effect. In addition, regulators of cellular reorganization and initiation of nascent protein synthesis were detected.
Analysis of Gene Expression in Ang-(1-7)-Treated RMVECs
To add depth to the Ang-(1-7)-stimulated MAS1 receptor signaling pathway data from the proteomic MS/MS analysis of the immunoprecipitation results, expression of common angiogenesis-related genes in response to 100 nmol/L Ang-(1-7) stimulation of RMVECs was examined according to previous literature. 26 The response to Ang-(1-7) treatment of RMVECs was assessed (Table 2 ) and related to the proteomic MS/MS data. Significant gene expression changes (P<0.05) were observed in 25 of the 84 genes (30%) analyzed (Table 2) , including growth factor/G-protein signaling, signal transduction regulation, and transcriptional regulation. Interestingly, vascular endothelial growth factor receptor 1 (VEGFR1, Vegfr1/Flt1, 3.02-fold; P=0.050) and vascular endothelial growth factor receptor 2 (VEGFR2, Vegfr2/Kdr, 7.65-fold; P=0.011) were upregulated, suggesting a link to components of RAS signaling identified in the proteomic analyses that have been shown to mediate angiogenesis through vascular endothelial growth factor family signaling. 27 Numerous other significant changes in gene expression of important angiogenesis and vasoreactive signal molecules were observed related to G-protein signaling, including CDC42 (cell division control protein 42; Cdc42; 1.22-fold; P=0.047) and RAC2 (Ras-related C3 botulinum toxin substrate 2; Rac2; 6.65-fold; P=0.009), ERK1/2 and mitogen-activated protein kinase (MAPK) signaling, including MEK2 (mitogen-activated protein kinase kinase 2; Map2k2; 1.57-fold; P=0.005) and p38MAPK (Mapk13; 5.57-fold; P=0.002), phosphoinositol signaling, and phospholipase signaling ( 
022).
Interestingly, the high-dose AngII (10× low-dose AngII) stimulation of the RMVECs exhibited a marked decrease in AKT, VEGFR, MAPK, phosphoinositol, and phospholipase signaling molecules (P<0.05) that were upregulated by Ang-(1-7) ( Table 2) or low-dose AngII stimulation (Table 3) .
Bioinformatics Signaling Pathway Analysis of Ang-(1-7)-Mediated Mas1 Signaling in the Endothelium
The results of a comprehensive bioinformatic analysis of the proteomic and real-time-polymerase chain reaction data set for pathway mapping of Ang-(1-7)-stimulated Mas1 receptor signaling in RMVECs is summarized in Figure 3 . On the basis of the proteomic data, a cell surface complex consisting of extracellular matrix proteins, the Mas1 receptor, and AT 1 R seem to form and signal through the Rho family of GTPases (RHO, RAC, and RAS). Further bioinformatics pathway analysis of the data indicated that G-protein signaling acted upstream of the PI3K/PRKD1 (serine/threonine protein kinase D1)/AKT and MAPK/ERK signaling pathways important for endothelial function, angiogenesis, and vasodilation. General trends observed implicated p38MAPK and ERK1/2 signaling as the important mediators of angiogenesis and vasodilation processes. This analysis suggests a possible convergence of the Ang-(1-7)/Mas1 receptor signaling in this study with previously known AngII/ AT 1 R signaling, especially on the p38MAPK and ERK1/2 signal cascades, leading to upregulation of VEGFR signaling as indicated by downstream gene expression analysis (Figure 3) . The Ang-(1-7)/Mas1 receptor signaling complex pathway data presented here is supported by previous literature showing that early stage changes in Ang-(1-7) induced phosphorylation and protein expression related to global changes in ERK1/2, AKT1, NFκB, and vascular endothelial growth factor signaling 19, 20 and further confirm the molecular basis of the cell survival and anti-inflammatory role of Mas1 receptor activation.
Ang-(1-7)-Dependent Activation of RMVEC Signaling
The bioinformatics signaling pathway analysis of Ang-(1-7)-mediated signaling in RMVECs indicated pathways crucial for angiogenesis and vasodilation. ERK1/2 and p38MAPK were 2 important protein regulators indicated by the activated Mas1 receptor immunoprecipitation proteomic MS/MS data and the Ang-(1-7)-stimulated RMVEC gene expression arrays. Therefore, the activation of ERK1/2 and p38MAPK was tested by monitoring Ang-(1-7)-induced phosphorylation in the RMVECs. Immunoblotting of ERK1/2 and p38MAPK, along with the phosphorylation of these molecules, in serumstarved (1% fetal bovine serum) RMVECs not treated and treated with Ang-(1-7) samples was used to monitor pathway activation (Figure 4) . RMVECs in complete media exhibited high ERK1/2 phosphorylation but little p38MAPK phosphorylation. However, the serum-starved RMVEC samples showed little ERK1/2 phosphorylation and high p38MAPK phosphorylation, suggesting that serum starvation suppressed ERK1/2 in our system but enhanced p38MAPK. Treatment of serum-starved RMVECs with 100 nmol/L Ang-(1-7) was able to significantly recover ERK1/2 phosphorylation back to levels of complete media after 15 minutes, whereas p38MAPK remained steady in activation. These data suggest that ERK1/2 is activated in an Ang-(1-7)/Mas1 receptor-dependent manner, whereas p38 MAPK is activated during serum starvation and maintained after Ang-(1-7) treatment. March 2017
Effects of ERK1/2 and p38MAPK Inhibition on Ang-(1-7)-Stimulated Mas1 Receptor-Mediated Angiogenesis
To validate specific signaling pathways shown to be of importance in the Ang-(1-7) stimulation of the Mas1 receptor by proteomic and real-time-polymerase chain reaction analyses, we tested the functional effects of key modulators ERK1/2 and p38MAPK.
RMVEC tube formation was performed for 24 hours in the presence or absence of 100 nmol/L Ang-(1-7) or AngII plus or minus ERK1/2 or p38MAPK antagonists according to the methods ( Figure 5 ). Ang-(1-7) and AngII stimulated an upward trend in RMVEC tube formation; however, only Ang-(1-7) resulted in a significant increase (P<0.001) versus RMVECs alone. The AngII data, coupled with the whole animal data in Figure 1 , suggest that All genes indicated significant fold change in gene expression (P≤0.05); biological processes include but are not limited to those above (N=3). AKT indicates serine/ threonine protein kinase AKT; Ang-(1-7), angiotensin 1 to 7; ERK, extracellular signal-related kinase; FLT, fms-like tyrosine kinase; MAPK, mitogen-activated protein kinase; NFκB, nuclear factor κ-light-chain-enhancer of activated B cell; PCR, polymerase chain reaction; PI3K, phosphatidylinositol 3-kinase; PRKD1, serine/threonine protein kinase D1; RAF, rapidly accelerated fibrosarcoma serine/threonine protein kinase; RAS, Ras GTPase; and VEGF, vascular endothelial growth factor. *Hundred nanomoles per liter Ang-(1-7) stimulated vs unstimulated endothelial cells. All genes indicated significant fold change in gene expression (P≤0.05); biological processes include but are not limited to those above (N=3). AKT indicates serine/ threonine protein kinase AKT; Ang-(1-7), angiotensin 1 to 7; ERK, extracellular signal-related kinase; FLT, fms-like tyrosine kinase; MAPK, mitogen-activated protein kinase; NFκB, nuclear factor κ-light-chain-enhancer of activated B cell; p38MAPK, p38 mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; PRKD1, serine/threonine protein kinase D1; RAF, rapidly accelerated fibrosarcoma serine/threonine protein kinase; RAS, Ras GTPase; RT-PCR, real-time polymerase chain reaction; and VEGF, vascular endothelial growth factor.
*Hundred nanomoles per liter Ang-(1-7) stimulated vs unstimulated endothelial cells.
other factors are required in vivo to aid in the AngII promotion of endothelial angiogenesis. Further experiments indicated that ERK1/2 inhibition resulted in complete loss of tube formation ability under all conditions. p38MAPK inhibition also resulted in significantly decreased tube formation versus control and stimulated conditions, but to a lesser extent than ERK1/2 inhibition. These data suggest that ERK1/2 is essential for angiogenesis processes in general and Ang-(1-7) signals directly through it, whereas p38MAPK may be one of the many MAPK upstream regulators of ERK1/2 making it a less essential molecule.
Effects of ERK1/2 and p38MAPK Inhibition on Low-Dose Ang-(1-7)-Stimulated MAS1 Receptor-Mediated Vasodilation
The influence of ERK1/2 and p38MAPK on ex vivo MCA endothelium-dependent Ach (10 −5 mol/L)-induced vasodilation was tested. Sprague Dawley rats on a high-salt diet to suppress the renin-angiotensin system were treated in vivo with AngII (5 ng·kg 10 μg/h) for 3 to 5 days as described in the methods. MCAs were then isolated and tested for vasoreactivity ex vivo. The ex vivo studies revealed that a chronic infusion of Ang- (1-7) or AngII restored MCA vasodilation responses to acetylcholine in comparison with the vehicle treatment; this phenotype was blocked by ERK1/2 inhibition ( Figure 6 ). Conversely, p38MAPK inhibition exhibited only slight ablation of acetylcholine-induced vasodilation in the MCA from rats receiving chronic AngII or Ang-(1-7) treatments. These data suggest that ERK1/2 is essential for the vasodilation response in conjunction with upstream MAPKs, not just those in the p38MAPK family.
Discussion
This study examined the impact of the administration of lowdose Ang-(1-7) in comparison with a low, equimolar dose of AngII on vascular dysfunction in an animal model with low renin-angiotensin system activity. The data here significantly expand the Ang-(1-7)/Mas1 receptor signaling pathway and add to the growing body of work, demonstrating an important distinction between the pathological effects of elevated or suppressed AngII and the beneficial vascular effects -(1-7) )-stimulated Mas1 receptor signaling pathway was generated. Signaling proteins annotated with blue lettering indicate those identified in the tandem MS analysis of the immunoprecipitation, annotated in red lettering were significantly increased during gene expression analysis, and annotated in black lettering were identified through both methods. Gray lettering indicates inferred signaling molecules. AKT indicates serine/threonine protein kinase AKT; AT1R, angiotensin II receptor type 1; CDC42, cell division control protein 42 homolog; ERK1/2, extracellular signal-related kinases1/2; FLT-3, fms-like tyrosine kinase 3; GAP/GEF, guanine nucleotide activating protein/guanine nucleotide exchange factor; MAPK, mitogen-activated protein kinase; MAS1, mas-related G-protein-coupled receptor 1; mTOR, mechanistic target of rapamycin; NFATC1/4, nuclear factor of activated T-cells 1/4; NMDA1, N-methyl-D-aspartate receptor 1; NOS3, nitric oxide synthase 3; NOTCH4, neurogenic locus notch homology protein 4; p38MAPK, p38 mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; PRKD1, serine/threonine protein kinase D1; RAF, rapidly accelerated fibrosarcoma serine/threonine protein kinase; RAS, Ras GTPase; RHO, Rho GTPase; sPLA2, secretory phospholipase A2; VEGF, vascular endothelial growth factor; VEGFR1, vascular endothelial growth factor receptor 1; and VEGFR2, vascular endothelial growth factor receptor 2.
of AngII normalization. It is well established that abnormally elevated levels of AngII stimulate superoxide production and endothelial dysfunction 2, 5, [29] [30] [31] [32] ; however, increasing evidence indicates that pathologically suppressed AngII levels also increase oxidant stress and endothelial dysfunction relative to physiologically normal plasma AngII levels. 6, 7, 33, 34 Numerous studies have now shown that suppression of AngII via high-salt diet disrupts vascular function and lowdose AngII infusion restores function via AT 1 R. 6, 7, 27 This challenges the belief that reduction in AngII is universally beneficial to vascular health, but it does not contradict the finding that normalizing pathologically elevated AngII levels is an effective intervention. Our data support this concept of an ideal range of plasma angiotensin peptides to promote effective endothelial function and suggest that an equimolar, low dose of Ang-(1-7) recapitulates the effects of this subpressor dose of AngII.
In previous work, we have consistently observed altered phenotypes of microvessel angiogenesis in response to electric stimulation by directly, genetically, or environmentally manipulating AngII levels and through pharmacological interventions, including angiotensin-converting enzyme inhibition and AT 1 R inhibition. demonstrate that Ang-(1-7), acting through the Mas1 receptor and not AT 1 R, is able to restore microvessel angiogenesis in response to electric stimulation ( Figure 1A ). Many studies have shown continuous infusion of Ang-(1-7) at levels ≤160× higher than used here generate Ang-(1-7)/Mas1 receptordependent effects that counteract the deleterious actions of high levels of AngII. 4, 13, 16 Our data suggest that at equimolar low doses, Ang-(1-7) and AngII have some complementary rather than antagonistic functions as seen with elevated AngII. [12] [13] [14] High levels of Ang-(1-7) inhibit vessel growth in tumor xenografts 40 ; however, a recent study has shown Ang-(1-7) stimulating a significant increase in sinusoidal endothelial cell sprouting and forming tubule structures out of cavernosal strips in culture. 41 We show enhancement of in vitro endothelial cell tube formation, in vivo skeletal muscle angiogenesis, and ex vivo MCA vasodilation by treatment with low-dose physiological concentrations of both Ang-(1-7) and AngII.
Although AT 1 R signaling has been well characterized, Mas1 receptor signaling mechanisms are only beginning to be elucidated. To further investigate the actions of low-dose Ang-(1-7) for comparison, we examined cellular signaling processes activated by Ang-(1-7) stimulation of the Mas1 receptor signaling complex. We then compared the results against low-and high-dose AngII RMVEC gene expression data (Table 3 ) and with known pathways influenced by AngII stimulation of AT 1 R. 2 We found substantial overlap in Ang-(1-7)-stimulated Mas1 receptor signaling and AngIIstimulated AT 1 R signaling. Gene expression analysis showed that equimolar, low doses of Ang-(1-7)/Mas1 and AngII/AT1 receptor-ligand interactions lead to the activation of similar pathways, whereas high-dose AngII exhibited downregulation of the same pathways (Tables 2 and 3 ). Initial functional tests showed that Ang-(1-7) significantly increased the ability of RMVECs to form tube-like structures in vitro (data not shown). Importantly, this verified that Ang-(1-7) stimulation had a functional effect on the specific endothelial cell population used for subsequent proteomic and gene expression signaling pathway analysis. Proteomic MS/MS analysis of Ang-(1-7)-stimulated Mas1 receptor signaling complexes implicated proteins involved in the regulation of G-protein, ERK/MAPK, PI3K/AKT/mTOR, CARD10/NFκB, and phosphoinositol signaling (Table 1) .
Gene expression analysis indicated that there were significant increases in expression of the VEGFR family, G-protein signaling, including CDC42, ERK1/2, and MAPK signaling, phosphoinositol signaling, and phospholipase signaling ( Table 2 ). The significant increase in expression of the VEGFR1 and VEGFR2 is significant because these are important downstream effectors resulting from RAS/MAPK/ ERK signaling and have been shown to mediate angiogenesis through vascular endothelial growth factor signaling in other models. 27 Together these data suggest that the Mas1 receptor signals through the RHO family of GTPases (RHO, RAS, RAC), ERK/MAPK, PI3K/PRKD1/AKT/mTOR-mediated cell survival signaling to promote normal endothelial function, cell survival, angiogenesis, and vasodilation ( Figure 3 ). In addition, the decreased detection of CARD10 after Ang-(1-7) stimulation suggests a downregulation of NFκB signaling and an anti-inflammatory response. These Ang-(1-7)/ Mas1 receptor signaling complex pathway data are supported by previous literature showing that Ang-(1-7) induced global changes in phosphorylation and protein expression related to ERK1/2, AKT1, NFκB, and vascular endothelial growth factor signaling. 19, 20 The direct signaling complex and pathways implicated by this data set correlate with early stage, but not later stage, global alterations of phosphorylation detected in the previous phosphoproteomic study on Ang-(1-7) signaling. 19 Interestingly, the gene expression analysis presented here for low-dose AngII stimulation demonstrated a similar upregulation in CDC42, VEGFR1, p38MAPK, and RAC signaling to that of Ang-(1-7) suggesting signaling overlap, whereas high-dose AngII exhibited a marked decrease in these signaling pathways supporting previously observed pathophysiologic phenotypes (Table 3) .
Modulation of AKT-dependent pathways by Ang-(1-7) stimulation of the Mas1 receptor, including increased mTOR and decreased NFκB activity, is supported by previous literature demonstrating that Ang-(1-7) regulates endothelial nitric oxide synthase activation through PIK3/PKB/AKT-dependent pathways. 10, 19, 20 In addition, it is known that AngII increases p38MAPK and ERK1/2 activities. 42 Pathway data presented here suggest p38MAPK and ERK1/2 involvement in Ang-(1-7)-mediated Mas1 signaling in the endothelium (Figure 3) . Previous studies have shown that Ang-(1-7) enhances AngII activation of ERK1/2 signaling in bone marrow-derived dendritic cells; a result that is blocked with the Mas1 antagonist A779. 43 These studies all point to a convergence between the AngII/AT 1 R and the Ang-(1-7)/Mas1 receptor signaling networks through ERK1/2 and p38MAPK signaling, as well as NFκB-mediated inflammatory responses. 3, 19, 44 Furthermore, our data implicate ERK1/2 and p38MAPK as candidate points of convergence for AngII/AT 1 R and Ang-(1-7)/Mas1 receptor signaling in the endothelium important for vasodilation and angiogenesis (Figures 5 and 6 ). However, our pathway activation data suggest that p38MAPK is activated in our system but not dependent only on Ang-(1-7), whereas ERK1/2 is an essential molecule for the Ang-(1-7)/Mas1 receptor vasodilation and angiogenic processes shown here (Figure 4 ). Further analysis of these targets using in vitro RMVEC tube formation after no stimulation, AngII stimulation, or Ang-(1-7) stimulation plus or minus ERK1/2 or p38MAPK inhibition indicated that AngII/AT 1 R and Ang-(1-7)/Mas1 receptor signaling converge on these molecules for the promotion of in vitro angiogenesis ( Figure 5 ). These data also suggest that ERK1/2 is a common point of convergence for angiogenesis pathways in general as it also inhibited in the vehicle control, whereas p38MAPK seems more specific for these renin-angiotensin system pathways. Similar conditions applied to rat MCAs indicated that AngII/AT 1 R and Ang-(1-7)/Mas1 receptor signaling through ERK1/2 was essential for vasodilation, whereas p38MAPK contributed but was not essential for this process, suggesting that there may be other MAPKs involved in signaling to ERK1/2 in this instance ( Figure 6 ). These results suggest that ERK1/2 is a point of essential convergence for acetylcholine-induced vasodilation in these pathways and angiogenesis signaling processes, including Ang-(1-7)/Mas1 and AngII/AT 1 R signaling.
It is important to note that AT 1 R was consistently identified as part of the Ang-(1-7)/MAS1 receptor signaling complex. It is well known that Ang-(1-7) does not signal through AT 1 R. Santos et al 8 showed that Ang-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas independent of AT 1 R. Our data in Figure 1 also demonstrate the specificity of Ang-(1-7) for the Mas1 receptor independent of AT 1 R stimulation. However, it is important to note that there have been previous reports of a functional interaction among the Mas1 receptor, AT 1 R, and AT 2 R that may be of importance to the receptor signaling. 45, 46 It has also been shown that EGF receptor transactivation is essential for ERK1/2 signaling mediated by AT 1 R. 27, 28 We cannot rule out a similar paradigm here given the presence of the AT 1 R in the Ang-(1-7)/MAS1 receptor signaling complex and the convergence of AT 1 R and Mas1 signaling. Although our vasodilation and angiogenesis data using AT 1 R and Mas1 receptor inhibitors show that Ang-(1-7) acts specifically through the Mas1 receptor (Figure 1) , we cannot rule out that there could be formation of a complex between the receptors at the cell surface required for signaling. This transactivation and the potential for tissue-/cell-specific differences in the balance between AT 1 R and Mas1 receptor signaling warrant examination in future studies.
The results of the current study suggest that AngII/ AT 1 R and Ang-(1-7)/Mas1 receptor signaling converge on an essential common pathway of importance for both angiogenesis and vasodilation in the renin-angiotensin system involving ERK1/2 and p38MAPK signaling. The study also indicated ERK1/2 signaling related specifically to phenotypes directed by AT 1 R and Mas1 receptor; it seems to be essential for global angiogenesis signaling processes as a point of convergence and demonstrated an Ang-(1-7) activation dependence in our system (Figure 4 ). These data, along with inhibition studies in Figures 5 and 6 , suggested that ERK1/2 was essential for Ang-(1-7)/Mas1 receptor-mediated vasodilation and angiogenesis. Overall, the innovative approach used for signal pathway analysis in combination with in vitro, ex vivo, and in vivo functional assays allowed for an increased understanding of Ang-(1-7)-stimulated Mas1 receptor signaling in relation to low, subpressor dose AngII (normal physiological levels) signaling through AT 1 R. Our data in endothelial cells and data from other laboratories in other cell types have shown that dosage of the peptide is a significant factor in how a cell responds to AngII or Ang-(1-7). 47, 48 There is also growing evidence that AngII/AT1and Ang-(1-7)/Mas1 signaling are co-occurring, dose-dependent, and more complex than once thought. 13 The complimentary action of equimolar, low-dose AngII and Ang-(1-7) suggests a delicate balance in the regulation of these 2 peptides at both the receptor and the intracellular signaling level.
